Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

124.09
-0.6464-0.52%
Post-market: 124.090.00000.00%19:30 EDT
Volume:26.40K
Turnover:3.29M
Market Cap:542.27M
PE:6.43
High:125.99
Open:125.88
Low:124.09
Close:124.74
52wk High:131.68
52wk Low:90.01
Shares:4.37M
Float Shares:4.37M
Volume Ratio:0.78
T/O Rate:0.60%
Dividend:1.06
Dividend Rate:0.85%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.63
PE(LYR):5.71

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

TIPRANKS
·
Sep 04

Wuhan Dazhong Dental Proposes Wang Hong as Executive Director to Replace Guo Jiaping

Reuters
·
Sep 04

J&J EVP, Worldwide Chair MedTech Timothy Schmid Disposes of 33,597 Common Shares Worth $9.23 Million

Reuters
·
Sep 04

Scotiabank Remains a Buy on AbbVie (ABBV)

TIPRANKS
·
Sep 04

BOB Capital Markets Cuts Abbott India PT on Slower Sales Growth Outlook

Reuters
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

Abbott VP, Controller John A. McCoy Jr Disposes of Common Shares Worth $8,685.45

Reuters
·
Sep 04

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 04

Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 04

Abbott Laboratories Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 04

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03